Sodium-glucose co-transporter 2 (SGLT2) is found in the proximal renal tubule and its function is to reabsorb filtered glucose from the urine.1,2 The SGLT2 inhibitor(s) (SGLT2i) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) are a class of antihyperglycemic medications that block this glucose reabsorption process, promoting the renal excretion of glucose and thereby resulting in the blood glucose lowering effect.2